BractonDeal Intel
Get full access
AcquisitionFinTech

Cullinan Oncology, Inc. acquired target

Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.

Deal tape row

Cullinan Oncology, Inc. -> target · $275.0 million

Cullinan received a $275.0 million upfront payment for the transaction, subject to customary purchase price adjustments, and is eligible for an additional $130.0 million tied to epidermal growth factor receptor (“EGFR”) exon20 non-small cell lung cancer (“NSCL

Open source record (SEC) ↗